Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325242 · ClinicalTrials.gov registry record · NA
Elbow Artery Embolization for Tennis Elbow
A NA study of Lateral Epicondylitis, Unspecified Elbow, sponsored by Siddharth Padia, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05325242: Recruiting NA study of Lateral Epicondylitis, Unspecified Elbow, sponsored by Siddharth Padia, MD.
NCT05325242 is a NA study of Lateral Epicondylitis, Unspecified Elbow that is actively recruiting participants, run by Siddharth Padia, MD. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05325242, a NA study of Lateral Epicondylitis, Unspecified Elbow, is actively recruiting participants, sponsored by Siddharth Padia, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical research study is to examine whether embolization treatment of an elbow artery is a safe and effective way to treat elbow pain, specifically pain from tennis elbow. Embozene is a medical device made by Varian marketed in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery to block the flow of blood to a specific region. One of the causes of pain in the setting of tennis elbow is increased blood flow going to the specific area of pain. In this study, we will investigate an experimental procedure to decrease the blood flow (embolize) to the specific region of the elbow that is causing the pain. This will be done by infusing Embozene particles into the specific blood vessel supplying the area of pain in the elbow. This is an investigational study to evaluate the safety and efficacy of elbow artery embolization (EAE) for the treatment of symptomatic lateral epicondylitis (tennis elbow).
Primary Outcome
Changes in QuickDASH (Disabilities of the Arm, Shoulder, and Hand) score as a measure of efficacy.
Conditions Studied
Interventions
- DEVICE Embozene particles
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT05325242 shows while recruiting
NCT05325242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Lateral Epicondylitis, Unspecified Elbow appearing as the primary indexed condition, and to 1 intervention - of which Embozene particles is the first listed.
NCT05325242 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05325242 about?
NCT05325242 is a clinical study titled "Elbow Artery Embolization for Tennis Elbow". The purpose of this clinical research study is to examine whether embolization treatment of an elbow artery is a safe and effective way to treat elbow pain, specifically pain from tennis elbow. Embozene is a medical device made by Varian marketed in the United States for the treatment of hypervascul...
What is the current status of trial NCT05325242?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2023-03-21. Estimated completion is 2027-12-31.
What conditions does trial NCT05325242 study?
This clinical trial studies the following conditions: Lateral Epicondylitis, Unspecified Elbow.
What interventions are being tested in trial NCT05325242?
The interventions under investigation include: Embozene particles (DEVICE).
Who is sponsoring clinical trial NCT05325242?
This trial is sponsored by Siddharth Padia, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05325242 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lateral Epicondylitis, Unspecified Elbow
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05325242's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI